Potential for α-Folate Receptor-Targeted Treatment for Ovarian Cancer
The majority of ovarian and a percentage of many other cancers express high levels of the folate receptor (FR). Folates and clinically approved antifolate drugs are largely transported into tumours and normal tissues via the high capacity reduced-folate carrier (RFC). A new generation of antifolates and folate–drug conjugates have been discovered that are preferentially transported via FRs and, because of highly restricted expression in normal tissues, they reach their targets selectively in tumours expressing the receptors. FRs are also being exploited by the development of therapeutic antibodies, folate-conjugated drug carriers and imaging agents. The preclinical and emerging clinical data demonstrate that the α-FR is an important therapeutic target in cancer with particular relevance in non-mucinous ovarian carcinoma.
KeywordsFolate receptor Folate–drug conjugates Antifolates ONX 0801 Ovarian cancer
- Armstrong DK, Bicher A, et al. (2008). Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse. Proc Am Soc Clin Onc 26: Abstract 5500.Google Scholar
- Bell-McGuinn KM, Konner J, et al. (2007). A phase I study of MORAb-003, a fully humanized monoclonal antibody against folate receptor alpha, in advanced epithelial ovarian cancer. Proc Am Soc Clin Onc 25: Abstract 5553.Google Scholar
- Messmann R, Amato R, et al. (2007). A phase II study of FolateImmune (EC90 with GP1-0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) in patients with refractory or metastatic cancer. Proc Am Soc Clin Oncol 25(18S): Abstract 13516.Google Scholar
- Ng C, Valenti M, et al. (2008). Efficacy and tolerability of the thymidylate synthase (TS) inhibitor, BGC 945 is mediated through its selective uptake via the alpha-folate receptor alpha-FR in IGROV-1 human tumor xenografts. Proc Am Assoc Can Res: Abstract 3289.Google Scholar
- Sausville E, Lorusso P, et al. (2007). A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors. Proc Am Soc Clin Onc 25(18S): 2577.Google Scholar